研究目的
To report the rate of mucositis with the preventive use of surface low-level laser therapy in patients with head and neck cancer.
研究成果
Despite a substantial dose to the oral mucosa, the rate of acute radiation-induced mucositis of grade ≥3 remains low in patients receiving extraoral low-energy laser during RT.
研究不足
The study has inherent bias. First, single-point laser was used at the discretion of the treating clinician on top of the surface laser and this might have influenced the mucositis rate. Second, concomitant treatments were heterogeneous, and patients receiving cetuximab were also included, although this treatment is known to be associated with severe cutaneous and mucosal side effects. Additionally, a recent phase II study showed that dexamethasone-based mouthwash can prevent mucositis in patients with breast cancer treated with evererolimus, but so far no guidelines exist about the use of local anaesthetics and corticosteroids in patients treated with RT for head and neck cancer.
1:Experimental Design and Method Selection:
Forty patients treated with definitive or adjuvant RT using volumetric arc therapy for squamous cell carcinoma of the head and neck were included. All patients were treated using photobiomodulation using surface low-level laser therapy.
2:Sample Selection and Data Sources:
Patients with histologically confirmed locally advanced HNSCC of the oral cavity, oropharynx or hypopharynx and treated with definitive or adjuvant RT with or without concomitant treatment at our institution between August 2014 and October 2015 were prospectively followed up.
3:List of Experimental Equipment and Materials:
Heltschl FL 3500 device, Pinnacle software, Novalis Truebeam STx.
4:Experimental Procedures and Operational Workflow:
Patients were treated in the sitting position. PBM using the surface laser Heltschl FL 3500 was administered transcutaneously using a continuous wavelength of 660 nm (visible red) (350 mW output power, 6 J/cm2).
5:2). Data Analysis Methods:
5. Data Analysis Methods: Acute toxicities were evaluated each week during treatment and 1 month thereafter by the same radiation oncologist and graded using the Common Terminology Criteria for Adverse Events (CTCAE) v. 3 and 4.
独家科研数据包,助您复现前沿成果,加速创新突破
获取完整内容